Targeted therapy for lung cancer is based on personalized medicine approach
SOMERVILLE, MA — October 12, 2022— ANDARIX Pharmaceuticals, a leader in the
discovery and development of targeted peptide therapy for cancer announced today that
it will present its technology for treating lung cancer patients at a clinical provider
conference. The conference will focus on the broad array of clinical trial technologies
and provider capabilities. The technology will be presented at the
OCT New England Conference in Boston, Massachusetts on October 12-13, 2022.
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin
peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated
and may produce prolonged stable disease and improved overall survival in advanced
lung cancer patients whose disease has continued to progress after failing other
therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is
expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and
pancreatic cancer patients. Along with its companion diagnostic that helps identify
patients most likely to respond – those with sufficient expression of the peptide’s target –
Tozaride could provide another treatment option for patients who are not eligible for, or
who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer,
developing both the imaging agents that can identify appropriate patients, as well as the
targeted therapies for these patients. The company’s products have progressed through
early clinical development. The Andarix technology is based on a proprietary
somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and
other cancers. Extensive research has demonstrated that somatostatin receptors are
highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors.
To learn more about Andarix, please visit www.andarix.com .